Pill Identifier App

Naratriptan Side Effects

It is possible that some side effects of naratriptan may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to naratriptan: oral tablet

As well as its needed effects, naratriptan may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking naratriptan, check with your doctor immediately:

More common
  • Chest pain (severe)
  • heaviness, tightness, or pressure in the chest, throat, or neck
  • sensation of burning, warmth, heat, numbness, tightness, or tingling
Less common
  • Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
Less common or rare
  • Convulsions (seizures)
  • irregular heartbeat
  • slow heartbeat

Some naratriptan side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

Less common
  • Anxiety
  • bone pain
  • change in taste sensation
  • chills or fever
  • difficulty with sleeping
  • eye problems
  • fainting
  • general feeling of discomfort or illness
  • joint pain
  • muscle or joint stiffness, tightness, or rigidity
  • pounding heartbeat
  • stomach discomfort or pain
  • trembling or shaking of the hands or feet
  • unusual tiredness or weakness

For Healthcare Professionals

Applies to naratriptan: oral tablet

Nervous system

Nervous system side effects have been reported in 7% of patients receiving 2.5 mg, 4% of patients receiving 1 mg, and 3% of patients receiving placebo. These effects included dizziness in 2% of patients receiving 2.5 mg and 1% of patients receiving 1 mg or placebo. These neurological adverse effects also include drowsiness in 2% of patients receiving 2.5 mg, 1% of patients receiving 1 mg, and <1% of patients receiving placebo. Malaise/fatigue have been reported in 2% of patients receiving either 2.5 or 1 mg, and 1% of patients receiving placebo.

Cerebral vascular accidents, including transient ischemic attack, subarachnoid hemorrhage, and cerebral infarction have been reported. Vertigo has been reported frequently. Tremors, disorders of cognitive function, sleep, and/or equilibrium have been reported infrequently. Compressed nerve syndromes, confusion, sedation, hyperesthesia, coordination disorders, paralysis of cranial nerves, decreased consciousness, dreams, altered sense of taste, neuralgia, neuritis, aphasia, hypoesthesia, motor retardation, muscle twitching and fasciculation, psychomotor restlessness, and convulsions have been reported rarely.

Atypical sensation has been reported in 4% of patients receiving 2.5 mg, 2% of patients receiving 1 mg, and 1% of patients receiving placebo. These sensations included paresthesias in 2% of patients receiving 2.5 mg, 1% of patients receiving 1 mg, and <1% of patients receiving placebo. Warm/cold temperature sensations have been reported frequently. A strange feeling and a burning/stinging sensation have been reported infrequently.[Ref]


Gastrointestinal side effects have been reported in 7% of patients receiving 2.5 mg, 6% of patients receiving 1 mg, and 5% of patients receiving placebo. These effects included nausea in 5% of patients receiving 2.5 mg, and 4% in patients receiving 1 mg or placebo. Colonic ischemia with abdominal pain and bloody diarrhea has also been reported in patients using naratriptan. Hyposalivation has been reported frequently. Dyspeptic symptoms, diarrhea, gastrointestinal discomfort and pain, gastroenteritis, and constipation have been reported infrequently. Abnormal liver function tests, abnormal bilirubin levels, hemorrhoids, gastritis, esophagitis, salivary gland inflammation, oral itching and irritation, reflux, regurgitation, and gastric ulcers have been reported rarely.[Ref]

While vomiting has been reported frequently, it occurred even more frequently in subjects receiving placebo than in patients receiving 2.5 mg.[Ref]


Other side effects have included pain and pressure sensation which have been reported in 4% of patients receiving 2.5 mg, and 2% of patients receiving 1 mg or placebo. Throat/neck symptoms have been reported in 2% of patients receiving 2.5 mg and 1% of patients receiving 1 mg or placebo. Pressure/tightness/heaviness sensations have been reported frequently. Drug-induced headache has also been reported.

Ear, nose, and throat infections have been reported frequently. Phonophobia, sinusitis, upper respiratory inflammation, and tinnitus have been reported infrequently. Allergic rhinitis, labyrinthitis, hearing difficulty, and hemorrhage of the ear, nose, and throat, have been reported rarely.

Chills and/or fever, edema and swelling have been reported infrequently. Spasms and mobility disorders have been reported rarely.[Ref]


Cardiovascular side effects including palpitations, increased blood pressure, tachyarrhythmias, and abnormal ECG (PR prolongation, QTc prolongation, ST/T wave abnormalities, premature ventricular contractions, atrial flutter, or atrial fibrillation), peripheral vascular ischemia, and syncope have been reported infrequently. Bradycardia, varicosities, hypotension, and heart murmurs have been reported rarely. Angina and myocardial infarction have also been reported.[Ref]


Endocrine side effects including thirst and polydipsia, dehydration, and fluid retention have been reported infrequently. Hyperlipidemia, hypercholesterolemia, hypothyroidism, hyperglycemia, glycosuria, ketonuria, and parathyroid neoplasm have been reported rarely.[Ref]


Ocular side effects including photophobia have been reported frequently. Blurred vision has been reported infrequently. Eye pain and discomfort, sensation of eye pressure, eye hemorrhage, dry eyes, difficulty focusing, and scotoma have been reported rarely.[Ref]


Hematologic side effects including increased white blood cells have been reported infrequently. Thrombocytopenia, quantitative red blood cell or hemoglobin defects, anemia, and purpura have been reported rarely.[Ref]


Respiratory side effects including bronchitis, cough, and pneumonia have been reported infrequently. Tracheitis, asthma, pleuritis, and airway constriction and obstruction have been reported rarely. Dyspnea has also been reported.[Ref]


Musculoskeletal side effects including muscle pain, arthralgia and articular rheumatism, muscle cramps and spasms, joint and muscle stiffness, tightness, and rigidity have been reported infrequently. Bone and skeletal pain have been reported rarely.[Ref]


Hypersensitivity side effects have been reported including anaphylaxis/anaphylactoid reactions, in some cases severe (e.g., circulatory collapse). Allergies and allergic reactions have been reported infrequently.[Ref]


Psychiatric side effects including anxiety, depressive disorders, and detachment have been reported infrequently. Aggression and hostility, agitation, hallucinations, panic, and hyperactivity have been reported rarely.[Ref]


Genitourinary side effects including bladder inflammation, polyuria, and diuresis have been reported infrequently. Urinary tract hemorrhage, urinary urgency, pyelitis, urinary incontinence, lumps of the female reproductive tract, inflammation of the breast, vagina, and/or fallopian tube, breast discharge, endometrium disorders, decreased libido, and breast lumps have been reported rarely.[Ref]


Dermatologic side effects including sweating, skin rashes, pruritus, and urticaria have been reported infrequently. Skin erythema, dermatitis and dermatosis, hair loss and alopecia, pruritic skin rashes, acne and folliculitis, allergic skin reactions, macular skin/rashes, skin photosensitivity, photodermatitis, skin flakiness, and dry skin have been reported rarely.[Ref]


1. "Product Information. Amerge (naratriptan)." Glaxo Wellcome, Research Triangle Park, NC.

2. Limmroth V, Kazarawa Z, Fritsche G, Diener HC "Headache after frequent use of serotonin agonists zolmitriptan and naratriptan." Lancet 353 (1999): 378

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.